Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
194 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2014', provides an overview of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 8 Global Markets Direct Report Coverage 8 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Overview 9 Therapeutics Development 10 Pipeline Products for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Overview 10 Pipeline Products for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Comparative Analysis 11 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Therapeutics under Development by Companies 12 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Therapeutics under Investigation by Universities/Institutes 16 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Products under Development by Companies 20 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Products under Investigation by Universities/Institutes 23 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Companies Involved in Therapeutics Development 24 Absynth Biologics Limited 24 Actelion Ltd 25 ActogeniX NV 26 Adenium Biotech ApS 27 AIMM Therapeutics B.V. 28 AmpliPhi Biosciences Corporation 29 AvidBiotics Corp. 30 C3 Jian, Inc 31 Cubist Pharmaceuticals, Inc. 32 Daiichi Sankyo Company, Limited 33 Evec, Inc. 34 GangaGen Inc. 35 ImmunoBiology Ltd. 36 Immuron Limited 37 Inovio Pharmaceuticals, Inc. 38 MedImmune, LLC 39 Merck & Co., Inc. 40 MGB Biopharma Limited 41 Microbiotix, Inc. 42 Micropharm Ltd 43 Nanotherapeutics, Inc. 44 Novabiotics Ltd 45 Novacta Biosystems Limited 46 Novartis AG 47 Oragenics, Inc. 48 Paratek Pharmaceuticals, Inc. 49 Pfizer Inc. 50 Procarta Biosystems Ltd 51 Prokarium Ltd. 52 Ranbaxy Laboratories Limited 53 Ruthigen, Inc. 54 Sanofi Pasteur SA 55 Sarum Biosciences Limited 56 Sequella, Inc. 57 Shire Plc 58 Sorrento Therapeutics, Inc. 59 Stellar Biotechnologies, Inc. 60 Summit Corporation plc 61 Synthetic Biologics, Inc. 62 The Medicines Company 63 Valneva SE 64 VaxInnate Corporation 65 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Therapeutics Assessment 66 Assessment by Monotherapy Products 66 Assessment by Combination Products 67 Assessment by Target 68 Assessment by Mechanism of Action 70 Assessment by Route of Administration 72 Assessment by Molecule Type 74 Drug Profiles 76 (actoxumab + bezlotoxumab) - Drug Profile 76 actoxumab - Drug Profile 77 AKT-10081 - Drug Profile 78 AmpliPHAGE-004 - Drug Profile 79 Antibodies for Enterocolitis - Drug Profile 80 AP-114 - Drug Profile 81 bezlotoxumab - Drug Profile 82 Biologic for Clostridium difficile Infections - Drug Profile 83 cadazolid - Drug Profile 84 clostridium difficile vaccine - Drug Profile 85 clostridium difficile vaccine - Drug Profile 86 clostridium difficile vaccine - Drug Profile 87 Clostridium Difficile Vaccine - Drug Profile 88 clostridium difficile vaccine - Drug Profile 89 clostridium difficile vaccine - Drug Profile 90 clostridium difficle vaccine - Drug Profile 91 Clostridium difficle vaccines - Drug Profile 92 CRS-3123 - Drug Profile 93 Drug for Clostridium difficile Infection - Drug Profile 94 Endolysin - Drug Profile 95 EV-029104 - Drug Profile 97 EV-029105A - Drug Profile 98 fidaxomicin - Drug Profile 99 Genetically Engineered Bacteria for Clostridium Difficile Enteropathy - Drug Profile 102 IC-84 - Drug Profile 103 IMM-529 - Drug Profile 104 INX-201 - Drug Profile 105 LFF-571 - Drug Profile 106 MBX-500 - Drug Profile 107 MGBBP-3 - Drug Profile 109 Monoclonal Antibodies for Clostridium difficile - Drug Profile 111 Monoclonal Antibody for Clostridium Dificile Infections - Drug Profile 112 Monoclonal Antibody to Inhibit Clostridium difficile Toxin A and Toxin B for Clostridium Difficile Infections - Drug Profile 113 Monoclonal Antibody to Inhibit Toxin A for Clostridium Difficile Infections - Drug Profile 114 MU-1140 - Drug Profile 115 NP-432 - Drug Profile 116 NVB-302 - Drug Profile 117 Oligonucleotide for Gram Negative Infections - Drug Profile 118 OraCAb - Drug Profile 119 oritavancin diphosphate - Drug Profile 120 P-4A - Drug Profile 123 PF-06425090 - Drug Profile 124 PolyCAb - Drug Profile 125 PRO-391 - Drug Profile 126 ramoplanin - Drug Profile 127 RBx-14255 - Drug Profile 128 RBX-2660 - Drug Profile 129 Recombinant Proteins to Disrupt Bacterial Cell Membrane for Bacterial Infections - Drug Profile 130 RUT-5860 - Drug Profile 131 SER-109 - Drug Profile 132 SER-262 - Drug Profile 133 Small Molecules to Inhibit DNA Synthesis for Infectious Diseases - Drug Profile 134 Small Molecules to Inhibit Dynamin for Clostridium Difficile Infections - Drug Profile 135 Small Molecules to Inhibit Riboswitch for MRSA and Clostridium Difficile Infections - Drug Profile 136 SMT-19969 - Drug Profile 137 SMT-21829 - Drug Profile 138 SQ-109 - Drug Profile 139 SQ-641 - Drug Profile 142 surotomycin - Drug Profile 143 SYN-004 - Drug Profile 144 Synthetic Peptide for Clostridium difficile Infections - Drug Profile 145 Tetracycline Derivatives for CDAD - Drug Profile 146 VAL-301 - Drug Profile 147 VP-20621 - Drug Profile 149 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Recent Pipeline Updates 150 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Dormant Projects 179 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Discontinued Products 180 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Product Development Milestones 181 Featured News & Press Releases 181 Appendix 189 Methodology 189 Coverage 189 Secondary Research 189 Primary Research 189 Expert Panel Validation 189 Contact Us 190 Disclaimer 190
List of Tables Number of Products under Development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), H2 2014 14 Number of Products under Development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Comparative Analysis, H2 2014 15 Number of Products under Development by Companies, H2 2014 17 Number of Products under Development by Companies, H2 2014 (Contd..1) 18 Number of Products under Development by Companies, H2 2014 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H2 2014 20 Comparative Analysis by Late Stage Development, H2 2014 21 Comparative Analysis by Clinical Stage Development, H2 2014 22 Comparative Analysis by Early Stage Development, H2 2014 23 Products under Development by Companies, H2 2014 24 Products under Investigation by Universities/Institutes, H2 2014 27 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Absynth Biologics Limited, H2 2014 28 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Actelion Ltd, H2 2014 29 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by ActogeniX NV, H2 2014 30 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Adenium Biotech ApS, H2 2014 31 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by AIMM Therapeutics B.V., H2 2014 32 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by AmpliPhi Biosciences Corporation, H2 2014 33 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by AvidBiotics Corp., H2 2014 34 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by C3 Jian, Inc, H2 2014 35 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Cubist Pharmaceuticals, Inc., H2 2014 36 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 37 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Evec, Inc., H2 2014 38 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by GangaGen Inc., H2 2014 39 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by ImmunoBiology Ltd., H2 2014 40 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Immuron Limited, H2 2014 41 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014 42 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by MedImmune, LLC, H2 2014 43 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Merck & Co., Inc., H2 2014 44 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by MGB Biopharma Limited, H2 2014 45 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Microbiotix, Inc., H2 2014 46 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Micropharm Ltd, H2 2014 47 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Nanotherapeutics, Inc., H2 2014 48 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Novabiotics Ltd, H2 2014 49 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Novacta Biosystems Limited, H2 2014 50 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Novartis AG, H2 2014 51 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Oragenics, Inc., H2 2014 52 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Paratek Pharmaceuticals, Inc., H2 2014 53 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Pfizer Inc., H2 2014 54 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Procarta Biosystems Ltd, H2 2014 55 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Prokarium Ltd., H2 2014 56 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Ranbaxy Laboratories Limited, H2 2014 57 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Ruthigen, Inc., H2 2014 58 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Sanofi Pasteur SA, H2 2014 59 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Sarum Biosciences Limited, H2 2014 60 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Sequella, Inc., H2 2014 61 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Shire Plc, H2 2014 62 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Sorrento Therapeutics, Inc., H2 2014 63 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Stellar Biotechnologies, Inc., H2 2014 64 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Summit Corporation plc, H2 2014 65 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Synthetic Biologics, Inc., H2 2014 66 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by The Medicines Company, H2 2014 67 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Valneva SE, H2 2014 68 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by VaxInnate Corporation, H2 2014 69 Assessment by Monotherapy Products, H2 2014 70 Assessment by Combination Products, H2 2014 71 Number of Products by Stage and Target, H2 2014 73 Number of Products by Stage and Mechanism of Action, H2 2014 75 Number of Products by Stage and Route of Administration, H2 2014 77 Number of Products by Stage and Molecule Type, H2 2014 79 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics - Recent Pipeline Updates, H2 2014 154 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Dormant Projects, H2 2014 183 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Discontinued Products, H2 2014 184
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
